IDEXX Laboratories (IDXX) Projected to Post Earnings on Monday

IDEXX Laboratories (NASDAQ:IDXX) will likely be announcing its Q4 2025 results before the market opens on Monday, February 2nd. Analysts expect the company to announce earnings of $2.93 per share and revenue of $1.0723 billion for the quarter. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, February 2, 2026 at 8:30 AM ET.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.08. The company had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The firm’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.80 EPS. On average, analysts expect IDEXX Laboratories to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $693.85 on Monday. The firm has a 50-day simple moving average of $705.83 and a 200-day simple moving average of $656.34. The stock has a market capitalization of $55.40 billion, a price-to-earnings ratio of 55.02, a price-to-earnings-growth ratio of 3.71 and a beta of 1.67. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. IDEXX Laboratories has a 52 week low of $356.14 and a 52 week high of $769.98.

Insider Buying and Selling

In other news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This represents a 30.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.98% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Coldstream Capital Management Inc. increased its position in shares of IDEXX Laboratories by 10.2% during the third quarter. Coldstream Capital Management Inc. now owns 1,747 shares of the company’s stock valued at $1,116,000 after acquiring an additional 162 shares during the last quarter. Danske Bank A S acquired a new position in shares of IDEXX Laboratories in the 3rd quarter worth approximately $25,527,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of IDEXX Laboratories during the 3rd quarter worth approximately $36,000. Hancock Whitney Corp boosted its position in shares of IDEXX Laboratories by 8.3% during the 3rd quarter. Hancock Whitney Corp now owns 3,133 shares of the company’s stock worth $2,002,000 after purchasing an additional 240 shares during the period. Finally, Keystone Financial Group acquired a new stake in IDEXX Laboratories in the 3rd quarter valued at approximately $468,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on IDXX. JPMorgan Chase & Co. increased their price objective on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Barclays assumed coverage on IDEXX Laboratories in a research report on Monday, December 8th. They issued an “overweight” rating and a $850.00 price target for the company. Jefferies Financial Group reiterated a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price objective on IDEXX Laboratories in a research note on Monday, November 3rd. Finally, UBS Group raised their target price on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $763.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.